drugset / Trial / NCT02414685
First Line TIP in Poor Prognosis TGCTs.
NaSingle-groupOpen-labelTreatment
Summary
TIP in the 1st line treatment of GCTs patients with unfavorable decline of serum tumor markers after 1 cycle of the BEP regimen.TIP will be administered to the patient until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
Timeline
- Start
- 2015-04
- Primary completion
- 2020-06
- Completion
- 2020-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Ifosfamide | Small molecule | 1.2 g | Intravenous |
| Subject | Paclitaxel | Small molecule | 250 mg/m2 | Intravenous |